Baird Medical Wins "Most Valuable Investment Award" for AI Tumor Ablation Surgical Robot at 10th China Medical Industry Innovation Competition

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") has been honored with the "Most Valuable Investment Award" at the 10th China Medical Industry Innovation Competition with its revolutionary in-development product, the "AI Tumor Ablation Surgical Robot." This prestigious recognition marks a significant milestone in the advancement of AI and robotics integration that Baird Medical is developing in the medical field. 

AI & Robotics: Redefining the Paradigm of Precision Medicine

Baird Medical's AI Tumor Ablation Surgical Robot will be an intelligent surgical system that seamlessly integrates multimodal AI algorithms with high-precision robotic arm control. Its key innovations will include:

1. Autonomous Decision-Making & Dynamic Optimization – Using an AI-powered real-time learning framework, the system simultaneously analyzes intraoperative imaging, physiological data, and thermal field simulations to dynamically adjust ablation parameters with millimeter-level precision.
2. Multi-Technology Synergy Platform – Integrating microwave, radiofrequency, laser, and nano-knife ablation technologies, the AI algorithm optimizes surgical site selection, nodule characteristics, energy output, and ablation method, overcoming the limitations of traditional single-technique approaches.
3. End-to-End Intelligent Automation: Leveraging AI-driven precision, the system seamlessly integrates preoperative 3D lesion segmentation, millimeter-level path planning, and intraoperative micron-level fully automated surgery, followed by predictive postoperative outcome analysis. Surgeons serve as overseers, intervening only at critical junctures in a passive mode as needed. This transformative approach will effectively enhance surgical efficiency.

As the "brain" of the system, Baird Medical's proprietary AI-driven platform will offer three key technological advantages:

1. Establishing an Extensive Medical Knowledge Base – Integrates over 100,000 tumor ablation image cases and 50,000 pathology reports, enabling cross-modal data correlation and in-depth analysis.
2. Building a Self-Evolving Learning Architecture – Utilizes federated learning technology to enable secure data sharing across global partner hospitals, reducing model iteration cycles to just a few weeks.
3. Implementing Quantum-Optimized Pretraining – In future collaboration with quantum computing centers, leverages quantum optimization algorithms to overcome the computational bottlenecks of traditional deep learning, significantly accelerating inference speed.

World-Class R&D Team & Cutting-Edge Development: A Milestone in Medical Technology

This project will actively implement Baird Medical's R&D strategy of "Global Expertise + Local Innovation," built on three core pillars.

1. Building an Elite Interdisciplinary Team – Bringing together top-tier medical robotics experts from Nanyang Technological University, globally renowned oncologic surgeons, and former AI algorithm engineers from the Chinese Academy of Sciences. This core team has deep expertise in AI-driven medical applications and has collectively filed over 90 patents.
2. Establishing a Comprehensive Validation Framework – Implementing rigorous multi-center clinical simulations across 20 top-tier hospitals in the U.S., Europe, and China to ensure the system's safety, reliability, and efficacy in complex surgical environments.
3. Advancing an Ethics-Driven AI Design – Developing the world's first AI-powered surgical ethics decision module, incorporating real-time risk alerts and redundant operation validation to proactively mitigate surgical complications, with a targeted reduction to below 1%.

Expanding Applications: From Tumor Treatment to a Minimally Invasive Revolution

This cutting-edge system extends beyond the precise ablation of solid tumors such as thyroid nodules, breast nodules, liver cancer, and lung cancer—it also marks a breakthrough in chronic pain management. More notably, its modular design is expected to enable rapid adaptation for applications in neurosurgery (e.g., epilepsy lesion localization) and urology (e.g., prostate ablation).

The launch of Baird Medical's AI-powered tumor ablation robotic system represents not only a paradigm shift in the integration of AI and robotics but also a redefinition of excellence in medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system is transforming minimally invasive surgery from an experience-based practice to a data-driven discipline. As commercial deployment expands across 30+ countries, the future of intelligent healthcare is now within reach.

The development of Baird Medical's AI-powered tumor ablation surgical robot will not only set a benchmark for the integration of AI and robotics but also redefine the standards for high-quality medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system aims to transform minimally invasive surgery from an experience-based practice to a data-driven one. If successfully commercialized, the system is expected to initiate regulatory approvals and market expansion across more than 30 countries, bringing the future of intelligent healthcare within reach.